author-photo

Shah Rahimian

13

Papers

45

Citations

Citation Trend

Filter By

Papers (9) Sort By

Journal Conference Others

Tilsotolimod with ipilimumab drives tumor responses in anti-PD-1 refractory melanoma.

2021 Cancer Discovery
Show All
- Source
- Cite
- Save
Citations (4)
Abstract CT265: A phase 2 multicenter study to evaluate the efficacy of tilsotolimod in combination with nivolumab and ipilimumab for treatment of microsatellite-stable colorectal cancer (ILLUMINATE-206)

2020 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
1083MO Final results from ILLUMINATE-204, a phase I/II trial of intratumoral tilsotolimod in combination with ipilimumab in PD-1 inhibitor refractory advanced melanoma

2020 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (8)
1031P Tilsotolimod engages the TLR9 pathway to promote antigen presentation and type I IFN signaling in solid tumours

2020 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Abstract 4062: Activation of innate and adaptive immunity using intratumoral tilsotolimod (IMO-2125) as monotherapy in patients with refractory solid tumors: a phase Ib study (ILLUMINATE-101)

2019 Cancer Research
Show All
- Source
- Cite
- Save
Citations (2)
1195PSafety, efficacy, and immune effects of intratumoral tilsotolimod in patients with refractory solid tumours: Updated results from ILLUMINATE-101

2019 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Preliminary safety of deep/visceral (D/V) image guided (IG) intratumoral injection (ITI) of IMO-2125.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
1306TiPILLUMINATE 301: A randomized phase III comparison of IMO-2125 with ipilimumab (ipi) versus ipi alone in subjects with anti PD 1 refractory melanoma

2018 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (1)
A phase 2 study to evaluate the safety and efficacy of Intratumoral (IT) injection of the TLR9 agonist IMO-2125 (IMO) in combination with ipilimumab (ipi) in PD-1 inhibitor refractory melanoma.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (16)